Celregen CRG-002 iPSC-derived islets
Celregen Therapeutics
Allogeneic iPSC-derived pancreatic islet cells being tested in an early exploratory China study for diabetes with hypoglycemia unawareness or severe hypoglycemic events.
The scorecard
The study is designed for preliminary efficacy, but no insulin-independence results are posted.[1]
No human durability data yet; long-term iPSC-derived graft survival remains the key unknown.[1]
The registry describes allogeneic iPSC-derived islets, not immune-evasive cells, so immune-management burden is unresolved.[1]
Administration is by portal-vein infusion or transplantation beneath the anterior rectus sheath, less burdensome than major surgery but still procedural.[1]
Early study is small and limited to severe-hypoglycemia/hypoglycemia-unawareness populations.[1]
The full picture
CRG-002 belongs in the same broad race as zimislecel, SR-02 and other manufactured islet sources: make enough beta-like cells to transplant without relying on cadaveric donors. Its public record is still thin, so it is tracked as a horizon entry rather than a front-runner. The trial is important because it adds another allogeneic iPSC-derived islet candidate to human testing.
Coming soon
ETA · Early phase 1 enrolling by invitation; primary completion estimated 2028
Sources